↓ Skip to main content
Embed badge What is this page?

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

Overview of attention for article published in Translational Neurodegeneration, September 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)

Mentioned by

twitter
2 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
108 Mendeley

What is this page?

Summary Twitter Google+ Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
Published in
Translational Neurodegeneration, September 2013
DOI 10.1186/2047-9158-2-19
Pubmed ID
24011391
Authors

Kay Cheong Teo, Shu-Leong Ho

Abstract

There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying effects in Parkinson's disease (PD) for over 20 years in various clinical trials. This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD. Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug. Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles, some of which may be insurmountable.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 <1%
Unknown 107 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 27 25%
Student > Master 17 16%
Student > Ph. D. Student 14 13%
Researcher 13 12%
Student > Postgraduate 7 6%
Other 12 11%
Unknown 18 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 17 16%
Biochemistry, Genetics and Molecular Biology 15 14%
Medicine and Dentistry 15 14%
Pharmacology, Toxicology and Pharmaceutical Science 10 9%
Chemistry 10 9%
Other 20 19%
Unknown 21 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2016.
All research outputs
#6,464,551
of 12,440,396 outputs
Outputs from Translational Neurodegeneration
#72
of 128 outputs
Outputs of similar age
#61,464
of 160,120 outputs
Outputs of similar age from Translational Neurodegeneration
#1
of 1 outputs
Altmetric has tracked 12,440,396 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 128 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.3. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,120 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them

This page is provided by Altmetric.